Benign hematopoietic progenitors in chronic myeloid leukemia: Current status and future prospects
Tóm tắt
Many patients with chronic myeloid leukemia (CML) retain a certain degree of normal hematopoiesis at disease presentation. This fact, suspected on the basis of cytogenetic findings, has been confirmed by long-term bone marrow cultures (LTBMC) and the combined use of phenotypic and molecular studies. Based on the lack of HLA-DR expression, it has been possible to recognize a benign subpopulation within the stem-cell compartment in CML. Different in vitro techniques have been developed for the selection of these benign progenitors, including LTBMC, marrow incubation with cytolytic drugs or interferon, positive selection based on their phenotypic characteristics, and exposure to synthetic antisense oligodeoxynucleotides. In vivo selection with interferon or intensive chemotherapy is also possible. The primary goal of the selection of benign hematopoietic progenitors is their use for autotransplantation. To date, a few hundred CML patients have been submitted to the latter procedure using bone marrow or peripheral blood. The fact that the majority of them show evidence of persistent disease emphasizes the necessity for better selection methods of the benign progenitors, for intensifying the conditioning regimen to reduce the tumor burden as much as possible, and for the use of adjuvant therapy post-transplantation. Future trends include the refinement of positive selection methods, negative selection by taking advantage of the different stromal adhesiveness of the benign and malignant progenitors, or the use of autologous natural killer cells, antisense oligodeoxynucleotides, or specific antibodies to the bcr/abl junction region, and retroviral marking to determine the origin of relapse in autologous transplantation.
Tài liệu tham khảo
Agarwal R, Doren S, Hicks B, Dunbar CE (1993) Long-term culture of CML marrow on stem cell factor-deficient stroma favors benign progenitors. Blood 82 [Suppl 1]: 382a
Andrews RG, Singer JE, Berstein ID (1990) Human hematopoietic precursors in long-term culture: single CD34+ cells that lack detectable T-cell, B-cell and myeloid antigens produce multiple colony-forming cells when cultured with marrow stromal cells. J Exp Med 172:355–358
Barnett MJ, Eaves CJ, Phillips GL et al (1989) Successful autografting in chronic myeloid leukemia after maintenance of marrow in culture. Bone Marrow Transplant 4:345–351
Baum CM, Weissman IL, Tsukamoto AS, Buckle AM, Peault B (1992) Isolation of a candidate human hematopoietic stemcell population. Proc Natl Acad Sci USA 89:2804–2808
Becker M, Fabrega S, Belloc F, Rice A, Barbu V, Reiffers J (1993) Interferon gamma is effective for BM purging in a patient with CML. Bone Marrow Transplant 12:155–158
Bhatia R, Mc Glave PB, Wayner E, Verfaillie CM (1993) Interferon-α restores adhesion of CML progenitors to bone marrow stroma by correcting impaired β-1 integrin receptor function. Blood 82 [Suppl 1]:3317
Brandt L, Mitelman F, Panani A, Lenner HC (1976) Extremely long duration of chronic myeloid leukaemia with Ph' negative and Ph' positive bone marrow cells. Scand J Haematol 16:321–325
Brito-Babapulle F, Bowcock SJ, Marcus RE et al (1989) Autografting for patients with chronic myeloid leukaemia in chronic phase: peripheral blood stem cells may have a finite capacity for maintaining haemopoiesis. Br J Haematol 73:76–81
Buroughs J, Gupta P, Verfaillie CM (1994) Diffusible factors from the murine cell line M2-10B4 support human in vitro hematopoiesis. Exp Hematol (in press)
Calabretta B (1992) In vitro and in vivo suppression of Philadelphia + leukemic growth by bcr-abl anti-sense oligodeoxynucleotides. Proceedings of the 2nd International Conference on Chronic Myeloid Leukemia. Bologna, October 1992, abstract no. 61
Carella AM, Gaozza E, Raffo MR et al (1991) Therapy of acute-phase chronic myelogenous leukemia with intensive chemotherapy, blood cell autotransplant and cyclosporin A. Leukemia 5:517–521
Carlo-Stella C, Mangoni L, Piovani G, Almici C, Garau D, Caramatti C, Rizzoli V (1991) In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte-macrophage colony-stimulating factor. Bone Marrow Transplant 8:265–273
Cashman JD, Eaves AC, Raines EW, Ross R, Eaves CJ (1990) Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. I. Stimulatory role of a variety of mesenchymal cell activators and inhibitory role of TGF-B. Blood 75:96–101
Cervantes F, Rozman C, Ballesta F, Milá M (1982) Prognostic significance of cytogenetical studies in chronic granulocytic leukaemia. Scand J Haematol 28:77–81
Cervantes F, Robertson JE, Rozman C et al (1994) Longterm survivors in chronic granulocytic leukaemia: a study of the International CGL Prognosis Study Group. Br J Haematol 87:293–300
Clarkson B, Strife A (1993) Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment. Leukemia 7:1683–1721
Coulombel L, Kalousek DK, Eaves CJ, Guzta CM, Eaves AC (1993) Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl J Med 308:1493–1498
Daley GQ, Goldman JM (1993) Autologous transplant for CML revisited. Exp Hematol 21:734–737
De Fabriitis P, Amadori S, Calabretta B, Mandelli F (1993) Elimination of clonogenic Philadelphia-positive cells using BRC-ABL antisense oligonucleotides. Bone Marrow Transplant 12:261–265
Degliantoni G, Mangoni L, Rizzoli V (1985) In vitro restoration of polyclonal hematopoietis in a chronic myelogenous leukemia after in vitro treatment with 4-hydroxyperoxycyclophosphamide. Blood 65:753–757
Deisseroth AB, Zhang W, Cha Y et al (1992) New directions in the biology and therapy of chronic myeloid leukemia. Leuk Lymph 6:89–95
Dexter TM, Allen TD, Lajtha LG (1976) Conditions controlling the proliferation of hemopoietic stem cells in vitro. J Cell Physiol 91:335–344
Dowding C, Guo A, Osterholz J, Siczkowski M, Goldman J, Gordon M (1991) Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. Blood 78:499–505
Dubé ID, Kalousek DK, Coulombel L, Gupta CM, Eaves CJ, Eaves AC (1984) Cytogenetic studies in early myeloid progenitor compartments in Ph′-positive chronic myeloid leukemia. II Long-term culture reveals the persistence of Ph′-negative progenitors in treated as well as newly diagnosed patients. Blood 63:1172–1177
Dubé ID, Arlin ZA, Kalousek DK, Eaves CJ, Eaves AC (1984) Nonclonal hemopoietic progenitor cells detected in long-term marrow cultures from a Turner syndrome mosaic with chronic myeloid leukemia. Blood 64:1284–1287
Dunbar CE, Stewart FM (1992) Separating the wheat from the chaff: selection of benign hematopoietic cells in chronic myeloid leukemia. Blood 79:1107–1110
Eaves CJ, Barnett MJ, Eaves AC (1993) In vitro culture of bone marrow cells for autografting in CML. Leukemia 7 [Suppl 2]: 126–129
Editorial (1992) Chronic myeloid leukaemia: potential for antisense therapy. Lancet 2:1262–1263
Fauser AA, Kanz L, Bross KJ, Lohr GW (1985) T cells and probably B cells arise from the malignant clone in chronic myelogenous leukemia. J Clin Invest 75:1080–1092
Fiacchini M (1992) Prognostic study of alpha-interferon (IFN)-treated chronic myeloid leukemia (CML) patients. I. Predicting karyotypic response. Proceedings of the 2nd International Conference on Chronic Myeloid Leukemia, Bologna, October 1992, p 99
Fialkow PJ, Jacobson RJ, Panayannopoulu T (1977) Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet, and monocyte/macrophage. Am J Med 63:125–130
Finney R, Mc Donald GA, Baikie AG, Douglas AS (1972) Chronic granulocytic leukaemia with Ph′ negative cells in bone marrow and a ten-year remission after bulsulphan hypoplasia. Br J Haematol 23:283–288
Gale RP, Butturini A (1992) Can intensive chemotherapy cure chronic myelogenous leukemia? Leukemia 6:863–865
Goldman JM, Gale RP, Horowitz MM et al (1988) Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion. Ann Intern Med 108:806–814
Goldman JM, Deisseroth AB (1992) Use of autotransplants in chronic myeloid leukemia. Bone Marrow Transplant 12:155–158
Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF (1987) Altered adhesive interactions with marrow stroma of haemopoietic progenitor cells in chronic myeloid leukaemia. Nature 288:342–345
Gorin NC, Najman A, van der Akker J, Aglietta M, Duhamel G (1982) Disappearance of Philadelphia chromosome after autologous bone marrow transplantation for treatment of chronic myeloid leukaemia in acute crisis. Lancet 1:44
Goto T, Nishikori M, Arlin Z et al (1982) Growth characteristics of leukemic and normal hematopoietic cells in Ph′ + chronic myelogenous leukemia and effects of intensive treatment. Blood 59:793–808
Hayata I, Sakurai M, Kakati S, Sandberg A (1975) Chromosomes and causation of human cancer and leukemia. XVI. Banding studies of chronic myelocytic leukemia, including five unusual Ph′ translocations. Cancer 36:1177–1191
Hogge DE, Coulombel L, Kalousek DK, Eaves CJ, Eaves AC (1987) Nonclonal hemopoietic progenitors in a G-6PD heterozygote with chronic myelogenous leukemia revealed after long-term marrow culture. Am J Hematol 24:389–394
Hoyle C, Gray R, Goldman J (1994) Autografting for patients with CML in chronic phase: an update. Br J Haematol 86:76–81
Jonas D, Lubbert M, Kawasaki ES, Henke M, Bross KJ, Mertelsman R, Herrmann F (1992) Clonal analyis of bcr-abl rearrangement in T lymphocytes from patients with chronic myeloid leukemia. Blood 79:1017–1023
Kantarjian HM, Vellekoop L, Mc Credie KB et al (1985) Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia. J Clin Oncol 3:192–200
Kantarjian HM, Talpaz M, Le Maistre ChF et al (1991) Intensive combination chemotherapy and autologous transplantation leas to the reappearance of Philadelphia chromosomenegative cells in chronic myelogenous leukemia. Cancer 67:2959–2965
Kantarjian H, Smith T, O'Brien S et al (1993) Prognostic factors for response and survical with alpha-interferon (IFN-A) therapy in early chronic-phase chronic myelogenous leukemia (CML). Blood 82 [Suppl 1]:378a
Körbling M, Burke Ph, Braine H, Elfenbein G, Santos G, Kaizer H (1981) Successful engraftment of blood derived normal hemopoietic stem cells in chronic myelogenous leukemia. Exp Hematol 6:684–690
Leemhuis T, Leibowitz D, Cox G, Srour EF, Tricot G, Hoffman R (1992) Selection of bcr/abl-negative progenitor cells from chronic myeloid leukemia marrow. In: Worthington-White DA, Gee AP, Gross S (eds) Advances in bone marrow purging and processing. Wiley-Liss Inc, New York, pp 231–237
Leemhuis T, Leibowitz D, Cox G, Siver R, Srour EF, Tricot G, Hoffman R (1993) Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow. Blood 81:801–807
Lisker R, Casas L, Mutchinick O, Pérez-Chávez F, Labardini J (1980) Late-appearing Philadelphia chromosome in two patients with chronic myelogenous leukemia. Blood 56:812–814
Martin PJ, Najfeld V, Hansen JA, Penfold GJ, Jacobson RJ, Fialkow PJ (1980) Involvement of the B-lymphoid system in chronic myelogenous leukemia. Nature 298:49–50
Mc Glave Ph, Mamus S, Villen B, Dewald G (1987) Effect of recombinant gamma interferon on chronic myelogenous leukemia bone marrow progenitors. Exp Hematol 15:331–335
Mc Glave PB, Arthur D, Miller WJ, Lasky L, Kersey J (1990) Autologous transplantation for CML using marrow treated ex vivo with recombinant human interferon gamma. Bone Marrow Transplant 6:115–120
Mc Glave P, Bartsch G, Anasetti C, Ash R, Beatty P, Gasejewski J, Kernan NA (1993) Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood 81:543–550
Mc Glave PB, De Fabriitis P, Goldman J et al (1994) Autologous transplant therapy for chronic myelogenous leukaemia prolongs survival: results from eight transplant groups. Lancet 343:1486–1488
Miller JS, Verfaillie CM, Mc Glave PB (1990) Adherent lymphokine-activated killer (A-LAK) cells preferentially suppress chronic myelogenous leukemia (CML) primitive progenitors. Blood 76 [Suppl 1]: 1195
Mortensen BT, Ernst P, Philip P (1988) Mafosfamide (AstaZ-7654) in vitro treatment of bone marrow does not eradicate Philadelphia-positive cells in chronic myeloid leukemia. Eur J Hematol 41:218–222
Pasternak G, Pasternak L (1994) Persistence of bcr-abl mRNA-expressing cells in long-term cultures established from chronic myeloid leukemic bone marrow or blood. Ann Hematol 68:9–14
Reiffers J, Trouette R, Marit G et al (1991) Autologous blood stem cell transplantation for chronic granulocytic leukaemia. Br J Haematol 77:339–345
Sharp JC, Joyner MW, Wayne AW et al (1979) Karyotypic conversion in Ph′-positive chronic myeloid leukaemia with combination chemotherapy. Lancet 1:1370–1372
Simonsson E, Oberg G, Bjiöreman M et al (1992) Intensive treatment in order to minimize the Ph-positive clone in chronic mycelogenous leukemia. Leuk Lymph 7 (suppl): 55–57
Singer JW, Arlin ZA, Najfeld V, Adamson JW, Kempin SJ, Clarkson BD, Fialkow PJ (1980) Restoration of nonclonal hematopoiesis in chronic myelogenous leukemia (CML) following a chemotherapy-induced loss of the Ph′ chromosome. Blood 56:356–360
Smalley RV, Vogel J, Huguley CM jr, Miller D (1977) Chronic granulocytic leukemia: cytogenetic conversion of the bone marrow with cycle-specific therapy. Blood 50:107–113
Sokal JE (1980) Significance of Ph′-negative marrow cells in Ph′-positive chronic granulocytic leukemia. Blood 56:1072–1076
Sutherland HJ, Eaves CJ, Eaves AC, Dragowska W, Landsdorp PM (1989) Characterization and partial purification of human marrow cells capable of initating long-term hematopoiesis in vitro. Blood 74:1563–1570
Strife A, Lambeck C, Wisniewski D, Wachter M, Gulati SC, Clarkson BD (1988) Discordant maturation as the primary biological defect in chronic myelogenous leukemia. Cancer Res 48:1035–1041
Szcylik C, Skorski T, Nicolaides C et al (1991) Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 253:562–565
Talpaz M, Kantarjian HM, Kurzrock R, Trujillo JM, Gutterman JU (1991) Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia Philadelphia chromosome-positive patients. Ann Intern Med 114:532–538
Tura S (1993) Treatment of Ph-positive chronic myeloid leukemia with alph interferon (Roferon-A). The Italian Cooperative Study Group experience. Proceedings of the 2nd International Conference on CML, Bologna 1992. Leuk Lymph [Suppl 1]:153–157
Turhan AG, Humphries RK, Eaves CJ et al (1990) Detection of breakpoint cluster region-negative and nonclonal hematopoiesis in vitro and in vivo after transplantation of cells selected in cultures of chronic myeloid leukemia marrow. Blood 76:2404–2410
Udomsakdi C, Eaves CJ, Landsdorp PM, Eaves AC (1992) Phenotypic heterogeneity of primitive leukemic hematopoietic cells in patients with chronic myeloid leukemia. Blood 80:2522–2530
Verfaillie C, Miller W, Kay N, Mc Glave P (1989) Adherent lymphokineactivated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity. Blood 74:793–797
Verfaillie C, Blakholmer K, Mc Glave P (1990) Purified primitive human hematopoietic progenitors with long-term in vitro repopulating capacity adhere selectively to irradiated bone marrow stroma. J Exp Hematol 172:509–520
Verfallie CM, Mc Carthy JB, Mc Glave PhB (1992) Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin an collagen type IV. J Clin Invest 90:1232–1241
Verfaillie CM, Miller WJ, Boylan K, Mc Glave PhB (1992) Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 79:1003–1010
Vogler WR, Winton EF, James S, O'Neill S, Granade G, Mallard G (1983) Autologous transplantation after karyotypic conversion to normal in blastic phase of chronic myelocytic leukemia. Am J Med 75:1080–1084
Von Denderen J, Hermans A, Meeuwswn T et al (1989) Antibody recognition of the tumor-specific bcr-abl joining region in chronic myeloid leukemia. J Exp Med 169:87–98
Wognum AW, Krystal G, Eaves CJ, Eaves AC, Lansdorp PM (1992) Increased erythropoietin-receptor expression in CD34-positive bone marrow cells from patients with chronic myeloid leukemia. Blood 79:642–649
Yuan T, Zhou YQ, Herst V et al (1992) Molecular approaches to purging of chronic myelogenous leukemia marrow in autologous transplantation. In: Worthington-White DA, Gee AP, Gross A (eds) Advances in bone marrow purging and processing. Wiley-Liss Inc, New York, pp 227–230